SynthesisLasers in medical science2026
Perioperative and oncological outcomes of thulium laser-ERBT versus conventional TURBT in non-muscle invasive bladder cancer: a meta-analysis of 2,934 patients.
Synthesis in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evaluation of thulium laser endoscopic en bloc resection versus conventional trans-urethral en bloc resection of primary non-muscle invasive bladder cancer: a randomized controlled trial.International urology and nephrology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thulium laser en bloc resection of bladder tumors (TmL-ERBT) represents a novel surgical approach for non-muscle-invasive bladder cancer (NMIBC), but its comparative advantages over conventional transurethral resection (TURBT) remain controversial. This meta-analysis aimed to evaluate perioperative safety, surgical quality, and oncological outcomes of TmL-ERBT versus TURBT. A systematic search of PubMed, Embase, Web of Science, and Cochrane Library identified comparative studies of TmL-ERBT versus TURBT. Perioperative complications, oncological outcomes, and surgical quality indicators were analyzed. Heterogeneity was assessed using I² statistics and subgroup analysis. The study quality was evaluated using the ROB2 tool. Evidence certainty was graded using the GRADEpro GDT. Fourteen studies comprising 2,934 patients (TmL-ERBT: n = 1,395; TURBT: n = 1,539) were included. TmL-ERBT demonstrated significant advantages in perioperative outcomes: shorter catheterization time (MD: -0.71 days, P = 0.001), reduced postoperative irrigation time (MD: -8.79 h, P = 0.0004), and decreased hospitalization time (MD: -0.63 days, P = 0.006). Operation duration showed no significant difference (MD: -2.66 min, P = 0.33). Safety outcomes favored TmL-ERBT with virtual elimination of obturator nerve reflex (OR: 0.04, P < 0.00001), reduced bladder perforation (OR: 0.26, P < 0.00001), decreased bleeding (OR: 0.10, P < 0.0001), and improved detrusor muscle presence (OR: 3.22, P = 0.03). Overall complication rates were comparable (OR: 0.75, P = 0.28). TmL-ERBT significantly improved recurrence-free rates at 3 months (OR: 1.70, P = 0.02) and 12 months (OR: 1.45, P = 0.04), but no difference at 24 months (OR: 1.03, P = 0.82) and ≥ 30 months (OR: 0.85, P = 0.13) than TURBT. Subgroup analyses revealed the advantages of TmL-ERBT were most pronounced in low-risk, smaller, solitary tumors. TmL-ERBT demonstrated superior perioperative outcomes, enhanced safety with reduced complications compared with conventional TURBT. These findings supported TmL-ERBT as a promising alternative for NMIBC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.